Business
OXBRYTA Sales Forecast and Market Size Analysis Report 2026-2034 with Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan
OXBRYTA's market potential is driven by its novel mechanism targeting HbS polymerization in sickle cell disease, leading to strong hemoglobin improvements. Its convenient oral, once-daily dosing enhances compliance, and label expansion increases its reach. Pfizer’s acquisition underscores its commercial promise.Dublin, May 15, 2026 (GLOBE NEWSWIRE) -- The "OXBRYTA Sales Forecast and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering. The OXBRYTA sales forecast repor
About this update from Pfizer, Inc.
[{"type":"image","alt":"Company Logo","displaySize":"","headline":null,"caption":"Company Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":36,"url":"https://media.zenfs.com/en/globenewswire.com/6a90a26a88cc04ec0d3fe15e0ab1be65"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/LAb6sww2pvOwp1YOuMHMug--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTUw/https://media.zenfs.com/en/globenewswire.com/6a90a26a88cc04ec0d3fe15e0ab1be65","width":300,"height":36},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/LAb6sww2pvOwp1YOuMHMug--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTUw/https://media.zenfs.com/en/globenewswire.com/6a90a26a88cc04ec0d3fe15e0ab1be65","width":300,"height":36}},"lazy":false},{"type":"text","content":"OXBRYTA's market potential is driven by its novel mechanism targeting HbS polymerization in sickle cell disease, leading to strong hemoglobin improvements. Its convenient oral, once-daily dosing enhances compliance, and label expansion increases its reach. Pfizer’s acquisition underscores its commercial promise.","length":317,"tagName":"p"},{"type":"text","content":"Dublin, May 15, 2026 (GLOBE NEWSWIRE) -- The "OXBRYTA Sales Forecast and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering.","length":169,"tagName":"p"},{"type":"text","content":"The OXBRYTA sales forecast report examines its market in the seven major regions, evaluating its clinical trials, competitive standing, and unique selling propositions to anticipate market changes and competitive pressures.","length":223,"tagName":"p"},{"type":"text","content":"OXBRYTA, developed by Global Blood Therapeutics and acquired by Pfizer, is FDA-approved for treating adults and children aged four and above with sickle cell disease. As a hemoglobin S polymerization inhibitor, voxelotor enhances hemoglobin oxygen affinity, reducing sickle cell polymer formation. Available in 300 mg or 500 mg tablets, its dosage is 1500 mg daily, with potential CYP3A4 interactions noted. Common side effects include gastrointestinal discomfort and fatigue.","length":476,"tagName":"p"},{"type":"text","content":"Key Factors Driving OXBRYTA Growth","length":34,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Novel Disease-Modifying Mechanism: OXBRYTA is pioneering as a hemoglobin S polymerization inhibitor, providing a diseas...